Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, multiple myeloma
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020,
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients.
3h
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
Pharmabiz
14d
ALX Oncology doses first patients for UMBRELLA phase 1/2 study with Sanofi to evaluate evorpacept in combination with Sarclisa
South San Franciso, California Friday, September 6, 2024, 16:30 Hrs [IST] ...
16d
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...
ENDPOINTS NEWS
5h
Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma
Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...
The American Journal of Managed Care
5h
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
17d
Sanofi: A Long-Term Cash Cow With High Dividends
Sanofi's Inhibrx acquisition strengthens its position in the global alpha-1 antitrypsin deficiency treatment market. See why ...
10d
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Tandem ...
Targeted Oncology
6h
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible Multiple Myeloma
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
multiple myeloma
Food and Drug Administration
Feedback